Literature DB >> 28141924

Classics in Chemical Neuroscience: Xanomeline.

Aaron M Bender1, Carrie K Jones1,2, Craig W Lindsley1,2,3.   

Abstract

Xanomeline (1) is an orthosteric muscarinic acetylcholine receptor (mAChR) agonist, often referred to as M1/M4-preferring, that received widespread attention for its clinical efficacy in schizophrenia and Alzheimer's disease (AD) patients. Despite the compound's promising initial clinical results, dose-limiting side effects limited further clinical development. While xanomeline, and related orthosteric muscarinic agonists, have yet to receive approval from the FDA for the treatment of these CNS disorders, interest in the compound's unique M1/M4-preferring mechanism of action is ongoing in the field of chemical neuroscience. Specifically, the promising cognitive and behavioral effects of xanomeline in both schizophrenia and AD have spurred a renewed interest in the development of safer muscarinic ligands with improved subtype selectivity for either M1 or M4. This Review will address xanomeline's overall importance in the field of neuroscience, with a specific focus on its chemical structure and synthesis, pharmacology, drug metabolism and pharmacokinetics (DMPK), and adverse effects.

Entities:  

Keywords:  Alzheimer’s disease; Xanomeline; allosteric modulation; antipsychotic; muscarinic acetylcholine receptors; schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28141924     DOI: 10.1021/acschemneuro.7b00001

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  9 in total

1.  A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity.

Authors:  Jerri M Rook; Jeanette L Bertron; Hyekyung P Cho; Pedro M Garcia-Barrantes; Sean P Moran; James T Maksymetz; Kellie D Nance; Jonathan W Dickerson; Daniel H Remke; Sichen Chang; Joel M Harp; Anna L Blobaum; Colleen M Niswender; Carrie K Jones; Shaun R Stauffer; P Jeffrey Conn; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2018-05-08       Impact factor: 4.418

2.  The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core.

Authors:  Jeanette L Bertron; Hyekyung P Cho; Pedro M Garcia-Barrantes; Joseph D Panarese; James M Salovich; Kellie D Nance; Darren W Engers; Jerri M Rook; Anna L Blobaum; Colleen M Niswender; Shaun R Stauffer; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2018-05-05       Impact factor: 2.823

3.  VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events.

Authors:  Julie L Engers; Elizabeth S Childress; Madeline F Long; Rory A Capstick; Vincent B Luscombe; Hekyung P Cho; Jonathan W Dickerson; Jerri M Rook; Anna L Blobaum; Colleen M Niswender; Darren W Engers; P Jeffrey Conn; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2018-09-04       Impact factor: 4.345

4.  Biased M1 receptor-positive allosteric modulators reveal role of phospholipase D in M1-dependent rodent cortical plasticity.

Authors:  Sean P Moran; Zixiu Xiang; Catherine A Doyle; James Maksymetz; Xiaohui Lv; Sehr Faltin; Nicole M Fisher; Colleen M Niswender; Jerri M Rook; Craig W Lindsley; P Jeffrey Conn
Journal:  Sci Signal       Date:  2019-12-03       Impact factor: 8.192

Review 5.  Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sean P Moran; James Maksymetz; P Jeffrey Conn
Journal:  Trends Pharmacol Sci       Date:  2019-11-08       Impact factor: 14.819

6.  Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs.

Authors:  Sophie J Bradley; Colin Molloy; Paulina Valuskova; Louis Dwomoh; Miriam Scarpa; Mario Rossi; Lisa Finlayson; Kjell A Svensson; Eyassu Chernet; Vanessa N Barth; Karolina Gherbi; David A Sykes; Caroline A Wilson; Rajendra Mistry; Patrick M Sexton; Arthur Christopoulos; Adrian J Mogg; Elizabeth M Rosethorne; Shuzo Sakata; R A John Challiss; Lisa M Broad; Andrew B Tobin
Journal:  Nat Chem Biol       Date:  2020-02-20       Impact factor: 15.040

7.  Xanomeline Protects Cortical Cells From Oxygen-Glucose Deprivation via Inhibiting Oxidative Stress and Apoptosis.

Authors:  Rujuan Xin; Zhongjian Chen; Jin Fu; Fuming Shen; Quangang Zhu; Fang Huang
Journal:  Front Physiol       Date:  2020-06-12       Impact factor: 4.566

8.  The Role of Orthosteric Building Blocks of Bitopic Ligands for Muscarinic M1 Receptors.

Authors:  Daniela Volpato; Michael Kauk; Regina Messerer; Marcel Bermudez; Gerhard Wolber; Andreas Bock; Carsten Hoffmann; Ulrike Holzgrabe
Journal:  ACS Omega       Date:  2020-12-01

9.  Discovery of a novel class of heteroaryl-pyrrolidinones as positive allosteric modulators of the muscarinic acetylcholine receptor M1.

Authors:  Paul K Spearing; Hyekyung P Cho; Vincent B Luscombe; Anna L Blobaum; Olivier Boutaud; Darren W Engers; Alice L Rodriguez; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Aaron M Bender
Journal:  Bioorg Med Chem Lett       Date:  2021-06-09       Impact factor: 2.940

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.